Intensifying tumour immunity through combination therapy.
Intensifying tumour immunity through combination therapy.
复制标题
DOI：
10.1016/s1470-2045(12)70051-7
复制
发表时间：
2012-05
期刊：
影响因子：
--
通讯作者：
Dranoff G
中科院分区：
文献类型：
--
作者：
Dranoff G
细胞毒性化学治疗药物的组合方案是癌症治疗的支柱。从历史上看，具有不同作用机制和非重叠毒性作用的几种药物的整合产生了一些实体和血液恶性肿瘤的治疗方案。目前，阻断特定致癌途径的靶向药物的临床开发也在沿着类似的路线进行。例如，选择性BRAF抑制剂的使用在大多数具有V600E突变BRAF等位基因的恶性黑素瘤患者中实现肿瘤消退，现在正在与MAP 2K（MEK）抑制剂一起评估，以抑制耐药克隆的出现。2
Combination regimens of cytotoxic chemotherapeutic drugs are a mainstay of cancer treatment. Historically, the integration of several agents with distinct mechanisms of action and non-overlapping toxic effects yielded curative regimens for some solid and haematological malignancies. 1 At present, the clinical development of targeted drugs that block specific oncogenic pathways is proceeding along a similar course. For example, selective BRAF inhibitors, the use of which achieves tumour regressions in most patients with malignant melanoma who harbour a V600E mutant BRAF allele, are now being assessed in conjunction with MAP2K (MEK) inhibitors in an effort to suppress the emergence of drug-resistant clones. 2